www.fool.com ·
halozyme halo q1 2026 earnings transcript
Topic context
This topic has been covered 340044 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedHalozyme's ENHANZE technology drives royalty revenue growth from partnered drugs (DARZALEX, VYVGART Hytrulo, PHESGO). New collaborations expand pipeline. No direct commodity or supply chain scarcity; impact is company-specific revenue/margin expansion via royalty stream. Sector: PHARMA_BIOTECH.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Halozyme Q1 2026 revenue $377M, +42% YoY
- Royalty revenue $241M, +43% YoY from ENHANZE-enabled products
- Full-year ENHANZE royalties expected >$1B
- Announced $1B share repurchase program, at least $400M in 2026
- Signed three new collaboration agreements including GSK
ENHANZE royalties expected >$1B in 2026; new collaborations with GSK support sustained revenue growth over 1-4 weeks; magnitude 5-10%.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- GLOBAL_HEALTHCAREmid
- GLOBAL_HEALTHCAREshort
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort